JUVEDERM
Live / Registered — Registered and renewed (as of 26 Aug 2019)
What this means for you
Registered since 03 Nov 2009. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 03 Nov 2029: the §8 & §9 renewal).
Record
- Serial number
- 78633566
- Registration number
- 3706974
- Mark type
- Word mark
- Filed
- 19 May 2005
- Published for opposition
- 14 Apr 2009
- Registered
- 03 Nov 2009
- Current term from
- 03 Nov 2019
- Next maintenance filing
- §8 & §9 renewal, due by 03 Nov 2029 (grace period to 03 May 2030)
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, all to be sold and marketed only to licensed physicians, surgeons, and healthcare professionals
Owner
- ALLERGAN, INC., IRVINE, CA, US
- ALLERGAN, INC., IRVINE, CA, US
- ALLERGAN, INC., IRVINE, CA, US
- Inamed Corporation, Santa Barbara, CA, US
Prior registrations
Board proceedings on this mark
- Counterclaim to cancel, in Opposition No. 91234098 — Allergan, Inc. v. Dermavita Limited Partnership and Energy Control Eood, filed 11 Apr 2017 (Terminated)
The owner also pleads this mark in 8 other Board proceedings.
Board decisions about this mark
Prosecution history
- 03 Dec 2020 — NOTICE OF SUIT
- 26 Aug 2019 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 26 Aug 2019 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 26 Aug 2019 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 26 Aug 2019 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 18 Jul 2019 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 18 Jul 2019 — TEAS SECTION 8 & 9 RECEIVED
- 03 Nov 2018 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 20 Apr 2018 — NOTICE OF SUIT
- 15 Aug 2017 — COUNTERCLAIM OPP. NO. 999999
- 28 Apr 2017 — NOTICE OF SUIT
- 28 Apr 2017 — NOTICE OF SUIT
- 26 Apr 2017 — NOTICE OF SUIT
- 26 Apr 2017 — NOTICE OF SUIT
- 15 Apr 2015 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED